A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial
Yeon Hee Park,Kyung Hun Lee,Joohyuk Sohn,Keun Seok Lee,Kyung Hae Jung,Jee Hyun Kim,Ki Hyeong Lee,Jin Seok Ahn,Tae Yong Kim,Gun Min Kim,In Hae Park,Sung-Bae Kim,Se Hyun Kim,Hye Sook Han,Young-Hyuck Im,Jin-Hee Ahn,Jung Yong Kim,Jahoon Kang,Seock-Ah Im +18 more
Reads0
Chats0
TLDR
Poziotinib showed meaningful activity in these heavily treated HER2‐positive mBCs and biomarker studies analyzed are warranted to support further evaluation of this treatment in such cases.Abstract:
Although the introduction of human epidermal growth factor receptor (HER)2-directed therapy including trastuzumab, pertuzumab, lapatinib and trastuzumab emtansine (T-DM1) in the treatment of HER2-positive metastatic breast cancers (mBCs) favorably changed the natural history of this disease, most cases of HER2-positive mBC will eventually progress Poziotinib is an oral pan-HER kinase inhibitor showing potent activity through irreversible inhibition of these kinases This open-label, multicenter phase II study was designed to evaluate the efficacy and safety of poziotinib monotherapy in patients with HER2-positive mBC who had progressed from more than two HER2-directed therapies Patients received 12 mg poziotinib once daily on a 14-day on/7-day off schedule Progression-free survival (PFS) as the primary endpoint, the objective response rate (ORR), overall survival (OS) and safety were evaluated From April 2015 to February 2016, 106 patients were enrolled in the trial from seven institutes in South Korea They had a median age of 51 years (range 30-76) and had received a median of four prior therapies including two HER2-directed therapies for advanced or metastatic cancers The median follow-up duration was 12 months The median PFS was 404 months (95% confidence interval [CI], 294-440 months), and median overall survival has not been reached The most common treatment-related adverse events were (total/grade ≥3) diarrhea (9623%/1415%), stomatitis (9245%/1226%) and rashes (6321%/377%) Poziotinib showed meaningful activity in these heavily treated HER2-positive mBCs Diarrhea and stomatitis were the major toxicities Biomarker studies analyzed are warranted to support further evaluation of this treatment in such casesread more
Citations
More filters
Journal ArticleDOI
HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance:
Sonia Pernas,Sara M. Tolaney +1 more
TL;DR: Add-on strategies of combining optimized targeted therapies could potentially improve outcomes for patients with HER2-positive breast cancer but may also allow de-escalation of treatment in some patients, potentially sparing some from unnecessary treatments, and their related toxicities and costs.
Journal ArticleDOI
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now.
Ilana Schlam,Sandra M. Swain +1 more
TL;DR: A review of currently approved TKIs for HER2+breast, key clinical trials, and their use in current clinical practice can be found in this paper, where the authors present a comparison of different types of therapies.
Journal ArticleDOI
Breast Cancer Treatments: Updates and New Challenges
TL;DR: In this article, a review summarizes current breast cancer treatments and explores the new treatment strategies from a personalized therapy perspective and the resulting challenges, including immunotherapy, conjugated antibodies, and targeting other metabolic pathways.
Journal ArticleDOI
Evolving standards of care and new challenges in the management of HER2-positive breast cancer.
TL;DR: The concept of treatment de‐escalation and escalation is increasingly important to optimally tailor therapy for patients with HER2‐positive BC and is a major focus of the current review.
Journal ArticleDOI
HER2-positive advanced breast cancer treatment in 2020
TL;DR: Questions about sequencing, treatment of triple positive disease and treatment choice after exposure to TDM-1 are re-opened, and choice of treatment and response evaluation may be substantially changed.
References
More filters
Journal ArticleDOI
American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff,M. Elizabeth H. Hammond,Jared N. Schwartz,Karen L. Hagerty,D. Craig Allred,Richard J. Cote,Mitchell Dowsett,Patrick L. Fitzgibbons,Wedad Hanna,Amy S. Langer,Lisa M. McShane,Soonmyung Paik,Mark D. Pegram,Edith A. Perez,Michael F. Press,Anthony Rhodes,Catharine M. Sturgeon,Sheila E. Taube,Raymond R. Tubbs,Gail H. Vance,Marc J. van de Vijver,Thomas M. Wheeler,Daniel F. Hayes +22 more
TL;DR: A testing algorithm that relies on accurate, reproducible assay performance, including newly available types of brightfield ISH, is proposed and strongly recommends validation of laboratory assay or modifications, use of standardized operating procedures, and compliance with new testing criteria to be monitored.
Journal ArticleDOI
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Charles E. Geyer,John K. Forster,Deborah Lindquist,Stephen Chan,C. Gilles Romieu,Tadeusz Pienkowski,Agnieszka Jagiełło-Gruszfeld,John Crown,Arlene Chan,Bella Kaufman,Dimosthenis Skarlos,Mario Campone,Neville Davidson,Mark S. Berger,Cristina Oliva,Stephen D. Rubin,S. Stein,David Cameron +17 more
TL;DR: Lapatinib plus capecitabine is superior to cape citabine alone in women with HER2-positive advanced breast cancer that has progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab.
Journal ArticleDOI
The ErbB signaling network: receptor heterodimerization in development and cancer
TL;DR: The role of ErbB receptors as normal signal transducers and their contribution to the process of malignant transformation during tumor development are concentrated on.
Journal ArticleDOI
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Jose Baselga,Sandra M. Swain +1 more
TL;DR: The role of two important family members of the epidermal growth factor receptor (Erbb) family is re-evaluate, the mechanisms of action are explored and preclinical and clinical data for new therapies that target signalling through these pivotal receptors are explored.
Journal ArticleDOI
Treatment of HER2-positive breast cancer: current status and future perspectives
Carlos L. Arteaga,Mark X. Sliwkowski,C. Kent Osborne,Edith A. Perez,Fabio Puglisi,Luca Gianni +5 more
TL;DR: This Review focuses on current treatment for patients with HER2-positive breast cancer and aims to update practicing clinicians on likely future developments in the treatment for this disease according to ongoing clinical trials and translational research.
Related Papers (5)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Rashmi Krishna Murthy,Sherene Loi,Alicia Okines,Elisavet Paplomata,Erika Hamilton,Sara A. Hurvitz,Nan Lin,Virginia F. Borges,Vandana G. Abramson,Carey K. Anders,Philippe L. Bedard,Mafalda Oliveira,Erik Jakobsen,Thomas Bachelot,Shlomit S. Shachar,Volkmar Müller,Sofia Braga,François Duhoux,Richard Greil,David Cameron,Lisa A. Carey,Giuseppe Curigliano,Karen A. Gelmon,Gabriel N. Hortobagyi,Ian E. Krop,Sibylle Loibl,Mark D. Pegram,Dennis J. Slamon,M Corinna Palanca-Wessels,Luke Walker,Wentao Feng,Eric P. Winer +31 more
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi,Cristina Saura,Toshinari Yamashita,Yeonhee Park,Sung Bae Kim,Kenji Tamura,Fabrice Andre,Hiroji Iwata,Yoshinori Ito,Junji Tsurutani,Junji Tsurutani,Joohyuk Sohn,Neelima Denduluri,Christophe Perrin,Kenjiro Aogi,Eriko Tokunaga,Seock-Ah Im,Keun Seok Lee,Sara A. Hurvitz,Javier Cortes,Caleb Lee,Shuquan Chen,Lin Zhang,Javad Shahidi,Antoine Yver,Ian E. Krop +25 more
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
A. Chan,Suzette Delaloge,Frankie A. Holmes,Beverly Moy,Hiroji Iwata,Vernon Harvey,Nicholas J. Robert,Tajana Silovski,Erhan Gokmen,Gunter von Minckwitz,Bent Ejlertsen,Stephen Chia,Janine Mansi,Carlos H. Barrios,Michael Gnant,Marc Buyse,Ira Gore,John A. Smith,Graydon Harker,Norikazu Masuda,Katarína Petráková,Angel Guerrero Zotano,Nicholas Iannotti,Gladys Rodriguez,Pierfrancesco Tassone,Alvin Wong,Richard Bryce,Yining Ye,Bin Yao,Miguel Martin +29 more